Compare Aventis Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs STRIDES PHARMA SCIENCE - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA STRIDES PHARMA SCIENCE SANOFI INDIA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 35.1 14.8 236.8% View Chart
P/BV x 6.1 0.9 702.0% View Chart
Dividend Yield % 1.4 0.6 255.5%  

Financials

 SANOFI INDIA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
STRIDES PHARMA SCIENCE
Mar-18
SANOFI INDIA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs6,8401,147 596.3%   
Low Rs4,630642 721.2%   
Sales per share (Unadj.) Rs1,203.1317.2 379.2%  
Earnings per share (Unadj.) Rs165.37.8 2,106.7%  
Cash flow per share (Unadj.) Rs209.925.1 837.6%  
Dividends per share (Unadj.) Rs84.002.00 4,200.0%  
Dividend yield (eoy) %1.50.2 655.1%  
Book value per share (Unadj.) Rs963.6274.3 351.4%  
Shares outstanding (eoy) m23.0389.50 25.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.82.8 169.1%   
Avg P/E ratio x34.7114.0 30.4%  
P/CF ratio (eoy) x27.335.7 76.5%  
Price / Book Value ratio x6.03.3 182.5%  
Dividend payout %50.825.5 199.4%   
Avg Mkt Cap Rs m132,07880,058 165.0%   
No. of employees `0003.32.5 131.7%   
Total wages/salary Rs m4,0684,341 93.7%   
Avg. sales/employee Rs Th8,393.811,325.8 74.1%   
Avg. wages/employee Rs Th1,232.41,731.4 71.2%   
Avg. net profit/employee Rs Th1,153.0280.1 411.7%   
INCOME DATA
Net Sales Rs m27,70828,394 97.6%  
Other income Rs m897941 95.4%   
Total revenues Rs m28,60529,334 97.5%   
Gross profit Rs m6,2353,965 157.2%  
Depreciation Rs m1,0271,540 66.7%   
Interest Rs m71,962 0.4%   
Profit before tax Rs m6,0981,403 434.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m2,29297 2,355.6%   
Profit after tax Rs m3,806702 542.1%  
Gross profit margin %22.514.0 161.1%  
Effective tax rate %37.66.9 542.0%   
Net profit margin %13.72.5 555.5%  
BALANCE SHEET DATA
Current assets Rs m15,92224,836 64.1%   
Current liabilities Rs m6,23518,993 32.8%   
Net working cap to sales %35.020.6 169.9%  
Current ratio x2.61.3 195.3%  
Inventory Days Days6471 89.7%  
Debtors Days Days21113 18.4%  
Net fixed assets Rs m7,53934,289 22.0%   
Share capital Rs m230895 25.7%   
"Free" reserves Rs m21,96223,651 92.9%   
Net worth Rs m22,19224,546 90.4%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m29,83965,437 45.6%  
Interest coverage x872.11.7 50,852.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.4 214.0%   
Return on assets %12.84.1 313.8%  
Return on equity %17.22.9 599.6%  
Return on capital %27.56.9 399.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58715,697 48.3%   
Fx outflow Rs m7,145735 971.6%   
Net fx Rs m44214,962 3.0%   
CASH FLOW
From Operations Rs m3,7391,871 199.9%  
From Investments Rs m-7315,826 -12.5%  
From Financial Activity Rs m-1,972-10,157 19.4%  
Net Cashflow Rs m1,036-2,615 -39.6%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 37.8 38.1%  
FIIs % 14.6 8.6 169.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.9 40.5%  
Shareholders   15,184 56,241 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 20, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS